DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2319568/coherus-biosciences-chrs-reports-q2-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2319568 Aug 08, 2024 - Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 33.33% and 13.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2319543/10x-genomics-txg-reports-q2-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2319543 Aug 08, 2024 - 10x Genomics (TXG) delivered earnings and revenue surprises of 31.91% and 1.46%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2319548/biolife-solutions-inc-blfs-reports-q2-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2319548 Aug 08, 2024 - BioLife Solutions (BLFS) delivered earnings and revenue surprises of 57.14% and 19.03%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2319549/century-aluminum-cenx-reports-q2-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2319549 Aug 08, 2024 - Century (CENX) delivered earnings and revenue surprises of -250% and 5.63%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2319555/potbelly-pbpb-tops-q2-earnings-and-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2319555 Aug 08, 2024 - Potbelly (PBPB) delivered earnings and revenue surprises of 60% and 0.59%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2319559/bloom-energy-be-reports-q2-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2319559 Aug 08, 2024 - Bloom Energy (BE) delivered earnings and revenue surprises of 0% and 6.38%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2319560/cambium-cmbm-reports-q2-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2319560 Aug 08, 2024 - Cambium (CMBM) delivered earnings and revenue surprises of -19.05% and 0.06%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2319531/oncternal-therapeutics-onct-reports-q2-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2319531 Aug 08, 2024 - Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 4.62% and 233.75%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2319535/gevo-inc-gevo-reports-q2-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2319535 Aug 08, 2024 - Gevo (GEVO) delivered earnings and revenue surprises of 0% and 33.84%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2319536/iovance-biotherapeutics-iova-reports-q2-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2319536 Aug 08, 2024 - Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 8.11% and 37.73%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? 0